Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer
BackgroundColorectal cancer (CRC) ranks as the third most common cancer globally. Neoadjuvant radiotherapy is the standard treatment for locally advanced rectal cancer; however, primary or acquired resistance often leads to treatment failure. Identifying new targets to overcome radiotherapy resistan...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2025-03-01
|
| Ráidu: | Frontiers in Pharmacology |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1557925/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|